Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau
Mild cognitive impairment (MCI) can be an early manifestation of Alzheimer’s disease (AD) pathology, other pathologic entities [e.g., cerebrovascular disease, Lewy body disease, LATE (limbic-predominant age-related TDP-43 encephalopathy)], or mixed pathologies, with concomitant AD- and non-AD pathol...
Main Authors: | Lauren E. McCollum, Sandhitsu R. Das, Long Xie, Robin de Flores, Jieqiong Wang, Sharon X. Xie, Laura E.M. Wisse, Paul A. Yushkevich, David A. Wolk |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | NeuroImage: Clinical |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213158221001613 |
Similar Items
-
Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-06-01) -
Tau and DNA Damage in Neurodegeneration
by: Luca Colnaghi, et al.
Published: (2020-12-01) -
Aging-Related Tau Astrogliopathy in Aging and Neurodegeneration
by: Heather McCann, et al.
Published: (2021-07-01) -
Tau and neurodegeneration : neuroimaging, genes, and biomarkers
by: Deters, Kacie Danielle
Published: (2017) -
Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
by: Xue‐Ning Shen, et al.
Published: (2020-01-01)